Notatki do odcinka
Harrow (HROW) stock analysis: 75% VEVYE growth vs debt — buy or sell deep dive
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Harrow, Inc. (HROW) and its aggressive commercial pivot from generic compounding into high-margin branded ophthalmic pharmaceuticals driven by VEVYE and TYRVAYA. With Q3 revenues growing 39% YoY to $99.3 million and shares trading at an EV-to-forward-sales multiple of 3.5x near 52-week…
Strona: flash.stocksentinel.ai

